Critical Therapeutics raising $54M

Critical Therapeutics of Lexington, Massachusetts, plans to raise $54.5 million in a private stock sale with a part of the funds going to relaunch its Zyflo asthma drug, acquired from Abbott last year. The launch is expected in the second half of this year. Other funds will go to advance its pipeline drugs.

- read this story from the AP for more

Suggested Articles

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.

The action will see Kiadis switch its attention to earlier-stage natural killer cell therapies against solid tumors and hematological cancers.